ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.
